Hattie Hayes

New research findings presented at this year's ARVO meeting compare two groups of paediatric patients in Nepal

Susana Chung, OD, PhD, spoke with us to discuss her presentation titled, "How similar is reading with central vision loss to reading in normal peripheral vision?" at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

David A Berntsen, OD, PhD, FAAO, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about axial growth after discontinuing soft multifocal contact lens wear in the BLINK2 study.

Age of vision loss onset has a stark impact on patients’ auditory processing and sensory substitution

Rick Lewis, chief medical officer of ViaLase, describes the company's nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.

Neda Nikpoor, MD, urges audience members to become more empowered in making small but meaningful, evidence-based changes in combating unconscious gender bias.

George O. Waring IV, MD, FACS, highlighted preliminary data from an open-label clinical trial, where his site was 1 of 4 in the US.

Deborah Gess Ristvedt, DO, shares highlights from her presentation and what these real-world cases mean for clinicians and their patients with glaucoma.

CRISPR manipulation presents opportunities and challenges.

At this year's ASCRS meeting in Boston, Massachusetts, Shoham-Hazon, MD provided highlights from his two paper presentations.

At the 2024 ASCRS meeting, David M. Lubeck detailed highlights from his presentations on the minimally invasive glaucoma surgery (MIGS) space.

At this year's ASCRS meeting in Boston, Massachusetts, Josefina Botta, MD, MSc, discussed her real-world experiences with the RayOne EMV toric lens.

At this year's ASCRS meeting Rom Kandavel, MD, of Colvard-Kandavel Eye Center in Los Angeles, California discussed the paper he presented at the meeting, which focused on IOP lowering and medication burden for patients who received the iStent inject.

Adam Muzychuk, MD, BSc, FRCSC discusses his presentation, "Outcomes of an ultra-low cylinder powered (0.90) toric versus non-toric in low astigmatic patients undergoing cataract surgery."

At the 2024 ASCRS Greg Kunst, CEO of Aurion Biotech relayed the latest news from Aurion and the company's work in cell therapies for corneal endothelial disease.

At this year's ASCRS meeting in Boston, Massachusetts, Ophthalmology Times Europe caught up with Eris Jordan, OD talked about the big plans the Boston-based startup has for the year ahead. Watch the full video to find out what's in store for the company and its novel cell therapy in Japan, Canada and the United States in 2024.

At this year's ASCRS meeting, J. Morgan Micheletti, MD talked about myriad research projects he discussed at the meeting and also emphasized the importance of the Young Eye Surgeons (YES).

At this year's ASCRS meeting in Boston, Massachusetts, Pete England gave an update on ViaLase's development on the first femtosecond laser for the treatment of open-angle glaucoma.

At this year's ASCRS meeting in Boston, Massachusetts, Leonard Borrmann, CEO at Centricity Vision, about the company's new product ZEPTOLink, including first-in-human data.

Neda Nikpoor, MD, shares highlights from her presentation on the Light Adjustable Lens during an ASCRS symposia on IOL calculations.

Elizabeth Yeu, MD, discusses a case report for how the triple procedure can be beneficial for different patient populations in her ASCRS presentation, 'Human corneal endothelial cell transplantation combined with cataract extraction and PCIOL in subject with corneal edema.'

Paul Harasymowycz, MD, details his presentation "Decade-Long Outcomes of Two First-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Primary Open-Angle Glaucoma" from this year's ASCRS meeting in Boston, Massachusetts.

William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.

Anthony Wallace, US Surgical vice president and general manager for Bausch + Lomb, reviews the latest advancements and updates in an interview with Ophthalmology Times.

Dan Tran, MD, shares key takeaways from his presentation, including a grading scale for incisions created with femtosecond laser.

Mark J. Gallardo, MD, highlighted the results from a phase 2 clinical trial of a travoprost intracameral implant in open-angle glaucoma or ocular hypertension.

George O. Waring IV, MD, FACS, provides an overview of his presentation at ASCRS 2024, highlighting outcomes for the safety and effectiveness of LASIK performed using an updated laser ablation algorithm for the correction of myopia and myopic astigmatism.

Sean Hanlon, CEO of CoFi, a payment software company, talks about the company's recent integration with CareCredit.

Rich Small, CEO of Neurotech Pharmaceuticals, provides an update on the months ahead for NT-501 encapsulated cell therapy

The positive opinion concerns authorization of bevacizumab gamma (ONS-5010/LYTENAVA), a formulation of bevacizumab for treatment of wet age-related macular degeneration (wet AMD).